Fujilai (301258.SZ): No plans for cellular immunotherapy

Gelonghui, May 10 | Fujilai (301258.SZ) said on the investor interactive platform that the company has no plans for cellular immunotherapy yet.

Gelonghui FinanceMay 10 03:33 ET

Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?

There will be major policies in the future

Gelonghui FinanceMay 7 01:29 ET

Fujilai (301258.SZ): R-lipoic acid produced by enzymatic method has been mass-produced and sold abroad

Gelonghui, May 6 | Fujilai (301258.SZ) said on the investor interactive platform that R-lipoic acid produced by the company's enzymatic method has been mass-produced and is currently still in the marketing stage. Whether it can completely replace the original process depends on various factors such as market demand and customer acceptance.

Gelonghui FinanceMay 6 03:33 ET

The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated

Trillion racetrack

Gelonghui FinanceMay 5 23:27 ET

Fujilai (301258.SZ): Net profit of 5.786,800 yuan in the first quarter decreased by 88.79% year on year

Gelonghui, April 22 | Fujilai (301258.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 96.2913 million yuan, down 38.47% year on year; net profit attributable to shareholders of listed companies was 5.7868 million yuan, down 88.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.1951 million yuan, down 92.87% year on year; basic earnings per share were 0.0631 yuan.

Gelonghui FinanceApr 22 09:33 ET

Fujilai (301258.SZ): Currently not involved in the production of anti-nuclear radiation products

Gelonghui, April 12 | Fujilai (301258.SZ) said on the investor interactive platform that the company is currently not involved in the production of anti-nuclear radiation products. In the pharmaceutical field, lipoic acid is used to treat various diseases such as diabetic peripheral neuropathy and neurological complications; in the field of health products, it has the effect of removing free radicals from the body and preventing lipid peroxidation, and can delay aging, beauty, and activate cells, and is used in oral nutritional products.

Gelonghui FinanceApr 12 03:34 ET